Recombinant Human Complement Factor H-related 2 His-tag, CF

When Recombinant Mouse Complement Component C3d (Catalog # 2655-C3) is immobilized at 2 µg/mL, 100 µL/well, Recombinant HumanComplement Factor H-related 2 (Catalog # 5484-CH) binds with an ED50 of25-150 ng/mL.

2 μg/lane of Recombinant Human Complement Factor H-related 2/CFHR2 was resolved with SDS-PAGE underreducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Bluestaining, showing bands at ~31 kDa and ~36 kDa under reducing conditions.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Complement Factor H-related 2 His-tag, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Mouse Complement Component C3d (Catalog # 2655-C3) is immobilized at 2 µg/mL (100 µL/well), Recombinant Human Complement Factor H-related 2/CFHR2 binds with an ED₅₀ of 25-150 ng/mL.
• Source: Mouse myeloma cell line, NS0-derived human Complement Factor H-related 2/CFHR2 protein
  Glu19-Glu268, with a C-terminal 10-His tag
• Accession #: P36980-1
• N-terminal Sequence: Glu19
• Protein/Peptide Type: Recombinant Enzymes
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 30 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 30-38 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in Tris and NaCl with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Complement Factor H-related 2 His-tag, CF

• CFHL2
• CFHL2FHR-2
• CFHR2
• Complement Factor Hrelated 2
• Complement Factor H-related 2
• factor H-related gene 2
• FHR2
• FHR2DDESK59
• H factor (complement)-like 3
• H factor-like 3
• H factor-like protein 2
• HFL3
• HFL3complement factor H-related protein 2

Background

Complement factor H-related protein 2 (CFHR2) is a ~30 kDa secreted, primarily homodimeric member of the factor H family of glycoproteins (1). CFHR2 is produced by hepatocytes and circulates as two differentially glycosylated isoforms (2). The human complement factor H protein family consists of the complement and immune regulators factor H, the factor H-like protein 1 (FHL-1) and five factor H-related proteins (CFHR-1 to -5) (3). The genes of this family are located on human chromosome 1q32, which is known as the regulator of complement activation (RCA) gene clusters (4). CFHRs are exclusively composed of individually folded protein domains termed short consensus repeats (SCRs) or complement control modules. CFHR2 contains 4 SCRs. Although considered group 1 CFHRs based on conserved N-termini (1), compared to CFHR2, human CFHR1 and CFHR5 show 67.5% and 34.5% aa identity, respectively. All CFHRs are capable of binding complement factor C3b, discriminate between self and non-self cell surfaces, and have been proposed to deregulate complement activation (3). CFHR2 inhibits the C3 convertase cleavage amplification loop by inhibiting terminal complement complex assembly (5). CFHR2 polymorphisms and deficiency were identified to correlate with risk of age-related macular degeneration (AMD) (6-8) implicating CFHR2 in human disease.

1. van Beek, A.E. et al. (2017) Front. Immunol. 18:1328.
2. Skerka, C. et al. (1992) J. Immunol. 148:3313.
3. Skerka, C. et al. (2013) Mol. Immunol. 56:170.
4. Diaz-Guillen, M.A. et al. (1999) Immunogenetics 49:549.
5. Eberhardt, H.U. et al. (2013) PLOS One 8:e78617.
6. Zhang, H. et al. (2008) BMC Med. Genet. 9:51.
7. Kubista, K.E. et al. (2011) Mol. Vis. 17:2080.
8. Cantsilieris, S. et al. (2018) Proc. Natl. Acad. Sci. 115:E4433.

Bioinformatics

• Uniprot:
  • P36980-1()